此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) (PINPOINT)

2026年6月11日 更新者:Odense University Hospital

Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer

This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative treatment. Participants receive one fraction of 24 Gy delivered with MR-guided stereotactic body radiotherapy (SBRT), which uses MRI to visualise the tumour and surrounding organs during treatment. The main goal is to assess safety (severe side effects). The trial also evaluates local tumour control, longer-term side effects, time until hormone (androgen deprivation) therapy is needed, survival, and quality of life. The trial aims to enrol 48 patients.

研究概览

详细说明

PINPOINT is a prospective, investigator-initiated, single-centre, single-arm phase 2 trial of single-fraction MR-guided SBRT in patients with nodal oligorecurrent prostate cancer. Eligible men have PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen following curatively intended local treatment.

All patients are simulated with MRI in treatment position and treated with 24 Gy in 1 fraction to the gross tumour volume (GTV) using inverse-planned step-and-shoot IMRT on an MR-linac. No CTV margin is added (CTV = GTV); PTV margins account for motion and set-up uncertainty. Normal-tissue constraints are prioritised over target coverage.

The primary endpoint is cumulative CTCAE v5 grade ≥4 treatment-related toxicity within 6 months. Sample size follows a Simon two-stage design (H0: grade 4-5 TRAE rate 15%; H1: 4%; one-sided α = 5%, power 80%), with an interim analysis after 6-month follow-up of the first 16 patients and a total of 48 patients. Follow-up continues for 5 years. Toxicity (CTCAE v5), quality of life (EQ-5D-5L, EORTC QLQ-C30) and patient-reported outcomes (PRO-CTCAE) are collected at baseline and through follow-up; PSA and PSMA-PET/CT (on rising PSA) follow standard of care.

研究类型

介入性

注册 (估计的)

48

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • Signed informed consent
  • Histologically proven initial diagnosis of adenocarcinoma of the prostate
  • ECOG performance status 0-2
  • Biochemical recurrence after curatively intended local treatment (radical prostatectomy and/or radiotherapy), with PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen
  • Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment
  • Life expectancy > 6 months
  • Lymph node size ≤ 2 cm

Exclusion Criteria:

  • Medical contraindications to MRI
  • Inability to tolerate the physical set-up required for SABR
  • Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury
  • Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)
  • Uncontrolled intercurrent illness

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single-fraction MR-guided SBRT
All participants receive 24 Gy in a single fraction to the GTV, delivered with MR-guided SBRT.
Participants will receive 24 Gy in 1 fraction to a lymph node.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants with cumulative CTCAE v5.0 grade ≥4 treatment-related adverse events
大体时间:Within 6 months after completion of radiotherapy
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects. Possible scores range from 0-5, with higher scores indicating a worse outcome.
Within 6 months after completion of radiotherapy

次要结果测量

结果测量
措施说明
大体时间
Number of participants with late adverse events (CTCAE v5.0)
大体时间:1, 1,5, 2, 3 and 5 years

The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effect.

Possible scores range from 0-5, with higher scores indicating a worse outcome.

1, 1,5, 2, 3 and 5 years
Percentage of participants free from local progression (PSMA-PET/CT-verified), estimated by time-to-event analysis
大体时间:From radiotherapy until local progression or last follow-up, up to 5 years
Defined as freedom from PSMA-verified relapse within the treated area. In the case of significant increase in PSA, a PSMA will be performed as to local guidelines. Local control will be evaluated at a lesion level, lesion by lesion. Within the treated area is defined as within or adjacent to the planning target volume (PTV).
From radiotherapy until local progression or last follow-up, up to 5 years
Median clinical progression-free survival
大体时间:From radiotherapy up to 5 years
Defined as time from inclusion to any new node or distant metastases recurrence.
From radiotherapy up to 5 years
Median time to initiation of palliative ADT (ADT-free survival)
大体时间:From inclusion up to 5 years
ADT-free survival is defined as the time from trial randomization to start of hormonal treatment
From inclusion up to 5 years
Number of participants with acute adverse events (CTCAE v5.0), by maximum grade
大体时间:Within 6 months after radiotherapy
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects. Possible scores range from 0-5, with higher scores indicating a worse outcome.
Within 6 months after radiotherapy
Median overall survival
大体时间:From inclusion up to 5 years
Overall survival is defined as time form inclusion to death from any cause
From inclusion up to 5 years
Mean change from baseline in EQ-5D-5L index (utility) score
大体时间:Baseline, 2 weeks, 3,6 and 12 months
The EQ-5D-5L is a standardized, validated generic instrument for health-related quality of life. It comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels. Responses are converted to a single summary index (utility) score using a country-specific (Danish) value set, anchored at 1 = full health and 0 = death, with negative values possible for health states considered worse than death; higher scores indicate better health-related quality of life. The outcome is reported as the mean change from baseline in the EQ-5D-5L index score at each assessment time point.
Baseline, 2 weeks, 3,6 and 12 months
Mean change from baseline in EORTC QLQ-C30 Global Health Status / QoL scale score
大体时间:Baseline, 2 weeks, 3, 6 and 12 months
The EORTC QLQ-C30 (version 3.0) is a validated cancer-specific questionnaire for assessing health-related quality of life in clinical trials. It contains 30 items comprising a global health status / quality of life scale, five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), and several single-item symptom and financial-impact measures. Raw scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual; for the global health status / QoL scale a higher score indicates better quality of life. This outcome is reported as the mean change from baseline in the global health status / QoL scale score at each assessment time point.
Baseline, 2 weeks, 3, 6 and 12 months
Number of participants reporting symptomatic adverse events as assessed by PRO-CTCAE
大体时间:Baseline, 2 weeks, 3,6 and 12 months
PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) is a validated patient-reported measurement system developed by the NCI to capture symptomatic toxicity in cancer clinical trials. A predefined subset of PRO-CTCAE items is used in this trial. Each symptom is rated by the patient over the prior 7 days across the applicable attributes - frequency (never to almost constantly), severity (none to very severe), and/or interference with usual or daily activities (not at all to very much) - each on a 5-point ordinal scale (scored 0-4). The outcome is reported as the number of participants in each response category per item and attribute at each assessment time point.
Baseline, 2 weeks, 3,6 and 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月1日

初级完成 (估计的)

2030年4月1日

研究完成 (估计的)

2035年9月1日

研究注册日期

首次提交

2026年6月3日

首先提交符合 QC 标准的

2026年6月3日

首次发布 (实际的)

2026年6月9日

研究记录更新

最后更新发布 (实际的)

2026年6月15日

上次提交的符合 QC 标准的更新

2026年6月11日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅